NCT04463108 (ARIANNA) is a clinical trial of No Intervention in Depressive Disorder, Major, sponsored by Janssen-Cilag S.p.A..

Who is sponsoring NCT04463108?

NCT04463108 is sponsored by Janssen-Cilag S.p.A..

What drugs are being tested in NCT04463108?

Interventions in NCT04463108: No Intervention.

What condition does NCT04463108 study?

NCT04463108 studies Depressive Disorder, Major, Suicidal Ideation.

Is NCT04463108 still recruiting?

NCT04463108 is currently completed. Last updated 27 April 2025.

Last reviewed 2025-04-27 · How we verify

NCT04463108: ARIANNA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Describe Routine Treatment Pathways in Participants With Major Depression and Active Suicidal Ideation With Intent in Italy

Completed Last updated 27 April 2025

What this trial tests

trial testing No Intervention in Depressive Disorder, Major in 136 participants. Completed in 8 November 2021.

Timeline

23 June 2020

Primary endpoint
8 November 2021

8 November 2021

Quick facts

Lead sponsor	Janssen-Cilag S.p.A.
Status	Completed
Study type	OBSERVATIONAL
Enrollment	136
Start date	23 June 2020
Primary completion	8 November 2021
Estimated completion	8 November 2021
Sites	24 locations across Italy

Drugs / interventions tested

No Intervention

Conditions studied

Depressive Disorder, Major — all drugs for Depressive Disorder, Major →
Suicidal Ideation — all drugs for Suicidal Ideation →

Sponsor

Janssen-Cilag S.p.A. — full company profile →

Who can join

Adults 18 to 74, any sex, with Depressive Disorder, Major or Suicidal Ideation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to describe the pharmacological and non-pharmacological treatment utilization pathways in Italian routine clinical practice of participants with Major Depressive Disorder (MDD) and active suicidal ideation with intent.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Routine treatment pathways in a cohort of patients with major depression and suicidality in Italy: the ARIANNA observational study.
Pompili M, Dell'Osso BM, Rosso G, Amore M, et al · · 2023 · cited 3× · PMID 37837942 · DOI 10.1016/j.comppsych.2023.152430
Routine treatment pathways of patients with major depression and active suicidal ideation with intent in Italy: interim results from the ARIANNA observational study
Pompili M, Bellomo A, Pilotto E, Rosso G, et al · · 2022
Cognitive impairment and frailty in depressed elderly
Arts M, Petrykiv S, Jonge L. · · 2022
Association of FKBP5 gene methylation and adolescents’ sex with depressive symptoms outcomes: a nested case-control study among Chinese adolescents
Li W, Lu C. · · 2022
Specifics of depression in epilepsy
Mitikhin V, Kuzminova M. · · 2022

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Depressive Disorder, Major

Currently open trials in the same condition.

NCT07227454 — A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder · Phase 3 · recruiting
NCT07258485 — A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major · recruiting
NCT07059234 — The Motor Activity - Subjective Energy (MASE) Project · NA · recruiting
NCT06982820 — Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia · NA · recruiting
NCT05553353 — Dosing rTMS for Depression Post-SCI · NA · recruiting

Other Janssen-Cilag S.p.A. trials

Trials by the same sponsor.

NCT04567602 — A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag · completed
NCT04439526 — A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis · completed
NCT03720561 — A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting · completed
NCT03577470 — An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and T · completed
NCT03131661 — A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targete · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04463108 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen-Cilag S.p.A.
Last refreshed: 27 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04463108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing